{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:51:39Z","timestamp":1791377499346,"version":"4.3.2"},"reference-count":127,"publisher":"Elsevier","isbn-type":[{"value":"9780443343858","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.009","type":"book-chapter","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:37:06Z","timestamp":1747251426000},"page":"271-304","source":"Crossref","is-referenced-by-count":4,"title":["Serotonergic psychedelics for depression: A comprehensive overview"],"prefix":"10.1016","author":[{"given":"A.M.","family":"Wingert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Agnorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Peill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Erritzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/bs.irn.2025.04.009_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","article-title":"Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics","volume":"66","author":"Abdallah","year":"2015","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/bs.irn.2025.04.009_bib3","article-title":"Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models","author":"Agnorelli","year":"2024","journal-title":"arXiv Preprint"},{"key":"10.1016\/bs.irn.2025.04.009_bib4","doi-asserted-by":"crossref","unstructured":"Aicher, H. D., Duffour, C., Liechti, M. E., Zullino, D., & Gasser, P. (2024). Treatment recommendations: Psychedelic-assisted therapy (PAT). Swiss Interest Group Psychedelic-Assisted Therapy (IG PAT). Retrieved April 23, 2025, from https:\/\/swisspsychedelic.ch\/wp-content\/uploads\/2024\/09\/Treatment_recommendations_PAT.pdf.","DOI":"10.4414\/sanp.2024.1488043038"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.009_bib5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2025.04.009_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: Therapeutic trends, challenges, and future directions","author":"Al-Harbi","year":"2012","journal-title":"Patient Preference and Adherence"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.009_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49026","article-title":"Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial","volume":"7","author":"Back","year":"2024","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib8","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2022.565","article-title":"Effects of psilocybin versus escitalopram on rumination and thought suppression in depression","volume":"8","author":"Barba","year":"2022","journal-title":"BJPsych Open"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.009_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/02698811231224217","article-title":"Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study","volume":"38","author":"Barbut Siva","year":"2024","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib10","doi-asserted-by":"crossref","first-page":"11731","DOI":"10.4088\/JCP.13r08672","article-title":"Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation","volume":"75","author":"Beach","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/bs.irn.2025.04.009_bib12","unstructured":"Beckley Psytech. (2024). Beckley Psytech announces positive initial data from phase IIa study of novel 5-MeO-DMT formulation BPL-003 for treatment resistant depression. Retrieved from https:\/\/www.beckleypsytech.com\/posts\/beckley-psytech-announces-positive-initial-data-from-phase-iia-study-of-bpl-003-for-treatment-resistant-depression#:\u223c:text=BPL%2D003%20is%20Beckley%20Psytech\u2019s,efficacy%20in%20patients%20with%20TRD."},{"issue":"2","key":"10.1016\/bs.irn.2025.04.009_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.31887\/DCNS.2006.8.2\/fbenazzi","article-title":"Various forms of depression","volume":"8","author":"Benazzi","year":"2006","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.009_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/20503245231170340","article-title":"A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness","volume":"9","author":"Brandt","year":"2023","journal-title":"Drug Science, Policy and Law"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/geroni\/igz036","article-title":"Effect size guidelines, sample size calculations, and statistical power in gerontology","volume":"3","author":"Brydges","year":"2019","journal-title":"Innovation in Aging"},{"issue":"R1","key":"10.1016\/bs.irn.2025.04.009_bib17","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1093\/hmg\/ddaa115","article-title":"Reviewing the genetics of heterogeneity in depression: Operationalizations, manifestations and etiologies","volume":"29","author":"Cai","year":"2020","journal-title":"Human Molecular Genetics"},{"issue":"45","key":"10.1016\/bs.irn.2025.04.009_bib18","doi-asserted-by":"crossref","first-page":"7472","DOI":"10.1523\/JNEUROSCI.1384-23.2023","article-title":"Beyond the 5-HT2A receptor: Classic and nonclassic targets in psychedelic drug action","volume":"43","author":"Cameron","year":"2023","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2025.04.009_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N, N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Research Bulletin"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.009_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"The Lancet Psychiatry"},{"issue":"15","key":"10.1016\/bs.irn.2025.04.009_bib21","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.009_bib22","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: Past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib23","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2025.04.009_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Frontiers in Integrative Neuroscience"},{"issue":"10128","key":"10.1016\/bs.irn.2025.04.009_bib25","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpdd.796","article-title":"Exposure-response analysis to assess the concentration-QTc relationship of psilocybin\/psilocin","volume":"10","author":"Dahmane","year":"2021","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.009_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","article-title":"Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition","volume":"26","author":"de la Torre","year":"2004","journal-title":"Therapeutic Drug Monitoring"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.009_bib30","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s44220-024-00298-y","article-title":"Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression","volume":"2","author":"Deco","year":"2024","journal-title":"Nature Mental Health"},{"key":"10.1016\/bs.irn.2025.04.009_bib31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00213-011-2434-x","article-title":"Pharmacology of ayahuasca administered in two repeated doses","volume":"219","author":"Dos Santos","year":"2012","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.009_bib32","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D\u2019Souza","year":"2022","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib33","unstructured":"Dubley, P. (2023, December 8). Psychedelic drug laws in Switzerland: A novel approach. TripSitter. Retrieved April 23, 2025, from https:\/\/tripsitter.com\/legal\/switzerland\/."},{"key":"10.1016\/bs.irn.2025.04.009_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: Observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial","volume":"76","author":"Erritzoe","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/02698811241237870","article-title":"Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression","volume":"38","author":"Erritzoe","year":"2024","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib36","article-title":"The antidepressant effects of vaporized N, N-dimethyltryptamine: An open-label pilot trial in treatment-resistant depression","author":"Falchi-Carvalho","year":"2024","journal-title":"Psychedelic Medicine"},{"key":"10.1016\/bs.irn.2025.04.009_bib37","series-title":"DMT research from 1956 to the edge of time","author":"Gallimore","year":"2015"},{"key":"10.1016\/bs.irn.2025.04.009_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.1998.tb08237.x","article-title":"Mechanisms of antiaddictive actions of ibogaine","volume":"844","author":"Glick","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"18","key":"10.1016\/bs.irn.2025.04.009_bib39","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.009_bib40","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.009_bib41","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.psychotherapy.1986.40.3.393","article-title":"Can drugs be used to enhance the psychotherapeutic process?","volume":"40","author":"Grinspoon","year":"1986","journal-title":"American Journal of Psychotherapy"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.009_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan","year":"2023","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib44","article-title":"The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame)","author":"Guss","year":"2020","journal-title":"PsyArXiv"},{"key":"10.1016\/bs.irn.2025.04.009_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behavioural Brain Research"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00213-011-2616-6","article-title":"Behavioral effects of \u03b1, \u03b1, \u03b2, \u03b2-tetradeutero-5-MeO-DMT in rats: Comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor","volume":"221","author":"Halberstadt","year":"2012","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","article-title":"How do antidepressants work? New perspectives for refining future treatment approaches","volume":"4","author":"Harmer","year":"2017","journal-title":"The Lancet Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41398-022-01926-w","article-title":"Structural neuroimaging measures and lifetime depression across levels of phenotyping in UK biobank","volume":"12","author":"Harris","year":"2022","journal-title":"Translational Psychiatry"},{"key":"10.1016\/bs.irn.2025.04.009_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: A history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Science, Policy and Law"},{"issue":"17","key":"10.1016\/bs.irn.2025.04.009_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.009_bib52","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: A systematic review and meta-analysis","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/02791072.2022.2044096","article-title":"The use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile: A systematic review","volume":"55","author":"Hodge","year":"2023","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/bs.irn.2025.04.009_bib54","series-title":"LSD: My problem child","author":"Hofmann","year":"2013"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib55","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.009_bib57","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","article-title":"Molecular, pharmacological and functional diversity of 5-HT receptors","volume":"71","author":"Hoyer","year":"2002","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.009_bib59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s44184-024-00068-9","article-title":"A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials","volume":"3","author":"Kishon","year":"2024","journal-title":"npj Mental Health Research"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","article-title":"Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: A meta-analysis of randomized clinical trials","volume":"72","author":"Kryst","year":"2020","journal-title":"Pharmacological Reports: PR"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib62","doi-asserted-by":"crossref","first-page":"22426","DOI":"10.1038\/s41598-021-01954-4","article-title":"Identifying subtypes of depression in clinician-annotated text: A retrospective cohort study","volume":"11","author":"Kung","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2025.04.009_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1477996","article-title":"Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: A systematic review of clinical trials","volume":"15","author":"Kwa\u015bny","year":"2024","journal-title":"Front Psychiatry"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.009_bib64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4088\/JCP.v63n0805","article-title":"Combining antidepressants for treatment-resistant depression: A review","volume":"63","author":"Lam","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.009_bib65","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.009_bib66","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/02698811231196877","article-title":"Psychological and physiological effects of extended DMT","volume":"38","author":"Luan","year":"2024","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.009_bib68","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Reports"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.009_bib69","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/02698811241232548","article-title":"Psychiatric risks for worsened mental health after psychedelic use","volume":"38","author":"Marrocu","year":"2024","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/bs.irn.2025.04.009_bib71","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpsychires.2024.10.009","article-title":"The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression","volume":"180","author":"Marwood","year":"2024","journal-title":"Journal of Psychiatric Research"},{"issue":"16","key":"10.1016\/bs.irn.2025.04.009_bib72","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1017\/S0033291723001411","article-title":"Cost-effectiveness of psilocybin-assisted therapy for severe depression: Exploratory findings from a decision analytic model","volume":"53","author":"McCrone","year":"2023","journal-title":"Psychological Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib73","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry: Official Journal of the World Psychiatric Association (WPA)"},{"key":"10.1016\/bs.irn.2025.04.009_bib74","article-title":"Efficacy of psilocybin for treating symptoms of depression: Systematic review and meta-analysis","volume":"385","author":"Metaxa","year":"2024","journal-title":"BMJ (Clinical Research ed.)"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.009_bib75","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cns.12099","article-title":"Ketamine pharmacology: An update (pharmacodynamics and molecular aspects, recent findings)","volume":"19","author":"Mion","year":"2013","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.009_bib76","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder","volume":"236","author":"Mithoefer","year":"2015","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.009_bib77","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nature Neuroscience"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.009_bib78","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatric Services"},{"key":"10.1016\/bs.irn.2025.04.009_bib79","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.009_bib80","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/bs.irn.2025.04.009_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/bph.17398","article-title":"The Australia story: Current status and future challenges for the clinical applications of psychedelics","author":"Nutt","year":"2024","journal-title":"British Journal of Pharmacology"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.009_bib82","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/bs.irn.2025.04.009_bib83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/7854_2023_451","article-title":"Psilocybin and Other Classic Psychedelics in Depression","volume":"66","author":"Nutt","year":"2024","journal-title":"Curr Top Behav Neurosci"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.009_bib84","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report","volume":"37","author":"Os\u00f3rio","year":"2015","journal-title":"Revista brasileira de psiquiatria"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib87","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychological Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib88","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2025.04.009_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1271152","article-title":"5-MeO-DMT for post-traumatic stress disorder: A real-world longitudinal case study","volume":"14","author":"Ragnhildstveit","year":"2023","journal-title":"Frontiers in Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.009_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009019","article-title":"Psychedelics and the human receptorome","volume":"5","author":"Ray","year":"2010","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib91","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jnc.15587","article-title":"The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)","volume":"162","author":"Reckweg","year":"2022","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2025.04.009_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1133414","article-title":"A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression","volume":"14","author":"Reckweg","year":"2023","journal-title":"Frontiers in Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib93","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"The American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib94","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.103.049882","article-title":"Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics","volume":"306","author":"Riba","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.009_bib95","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"European Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.009_bib96","doi-asserted-by":"crossref","first-page":"e2422181","DOI":"10.1001\/jamanetworkopen.2024.22181","article-title":"Interrupting the psychedelic experience through contextual manipulation to study experience efficacy","volume":"7","author":"Roseman","year":"2024","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib97","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"key":"10.1016\/bs.irn.2025.04.009_bib98","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib99","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The molecular mechanism of \u201cecstasy\u201d [3, 4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release","volume":"89","author":"Rudnick","year":"1992","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.009_bib100","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR\u204e D report","volume":"163","author":"Rush","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib101","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib102","first-page":"135","article-title":"Eight decades of measurement in depression measurement","volume":"4","author":"Santor","year":"2006","journal-title":"Measurement"},{"key":"10.1016\/bs.irn.2025.04.009_bib103","first-page":"59","article-title":"Antiquity of the use of new world hallucinogens","volume":"2","author":"Schultes","year":"1995","journal-title":"Archeomaterials"},{"key":"10.1016\/bs.irn.2025.04.009_bib104","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcbs.2019.11.002","article-title":"Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame","volume":"15","author":"Sloshower","year":"2020","journal-title":"Journal of Contextual Behavioral Science"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.009_bib105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib106","article-title":"Small Pharma reports positive top-line data from SPL026 (DMT)-SSRI drug interaction study in patients with major depressive disorder [Press release]","year":"2023","journal-title":"Business Wire"},{"key":"10.1016\/bs.irn.2025.04.009_bib107","article-title":"Small Pharma reports positive top-line results from Phase IIa trial of SPL026 in major depressive disorder [Press release]","year":"2023","journal-title":"BioSpace"},{"key":"10.1016\/bs.irn.2025.04.009_bib108","unstructured":"Small Pharma. (2022). Safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of intravenous dosing of SPL026 drug product (N, N-dimethyltryptamine fumarate; DMT Fumarate [A Serotonergic Psychedelic]) alone or in combination with selective serotonin reuptake inhibitors in patients with major depressive disorder [Press release]. Retrieved from https:\/\/www.isrctn.com\/ISRCTN10974027."},{"key":"10.1016\/bs.irn.2025.04.009_bib109","unstructured":"Small Pharma. (2023). Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder [Press release]. Retrieved from https:\/\/www.biospace.com\/small-pharma-reports-positive-top-line-results-from-phase-iia-trial-of-spl026-in-major-depressive-disorder#:\u223c:text=(TSXV%3A%20DMT)%20(OTCQB,treatment%20of%20Major%20Depressive%20Disorder%20(%E2%80%9C."},{"issue":"4","key":"10.1016\/bs.irn.2025.04.009_bib110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881120959609","article-title":"Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans","volume":"35","author":"Stenb\u00e6k","year":"2021","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib111","article-title":"Human hallucinogen interactions with drugs affecting serotonergic","volume":"7","author":"Strassman","year":"1992","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.04.009_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116337","article-title":"Efficacy and safety of psilocybin in the treatment of major depressive disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials","volume":"344","author":"Swieczkowski","year":"2025","journal-title":"Psychiatry Research"},{"key":"10.1016\/bs.irn.2025.04.009_bib113","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF02157378","article-title":"Dimethyltryptamine. Itsmetabolism in man: The relation of its psychotic","volume":"12","author":"Sz\u00e1ra","year":"1956","journal-title":"Experientia"},{"key":"10.1016\/bs.irn.2025.04.009_bib114","series-title":"Manifesting minds: A review ofpsychedelics in science, medicine, sex, and spirituality","first-page":"136","article-title":"Ethical caring in psychedelic work","author":"Taylor","year":"2014"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.009_bib115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5498\/wjp.v5.i3.330","article-title":"Pharmacologic approaches to treatment resistant depression: Evidences and personal experience","volume":"5","author":"Tundo","year":"2015","journal-title":"World Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib116","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Translational Psychiatry"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.009_bib117","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/bs.irn.2025.04.009_bib118","first-page":"56","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2a","key":"10.1016\/bs.irn.2025.04.009_bib119","first-page":"25","article-title":"The hallucinogenic mushrooms of Mexico and psilocybin: Abibliography (second printing, with corrections and addenda)","volume":"20","author":"Wasson","year":"1963","journal-title":"Botanical Museum Leaflets, Harvard University"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.009_bib120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"Journal of Humanistic Psychology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.009_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-8741(94)90051-5","article-title":"Bufo alvarius: A potent hallucinogen of animal origin","volume":"41","author":"Weil","year":"1994","journal-title":"Journal of Ethnopharmacology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.009_bib122","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/02698811231167848","article-title":"A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression","volume":"37","author":"Weiss","year":"2023","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.009_bib123","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0091-3057(99)00178-1","article-title":"The paradox of 5-methoxy-N,N-dimethyltryptamine: An indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors","volume":"65","author":"Winter","year":"2000","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/bs.irn.2025.04.009_bib124","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00412109","article-title":"Comparison of psilocin with psilocybin, mescaline and LSD-25","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"key":"10.1016\/bs.irn.2025.04.009_bib125","series-title":"Thirty years of psychedelicresearch: The Spring Grove experiment and its sequels","author":"Yensen","year":"1992"},{"key":"10.1016\/bs.irn.2025.04.009_bib126","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","article-title":"The impact of ayahuasca on suicidality: Results from a randomized controlled trial","volume":"10","author":"Zeifman","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.009_bib127","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-020-05692-9","article-title":"Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial","volume":"238","author":"Zeifman","year":"2021","journal-title":"Psychopharmacology (Berl)"}],"container-title":["International Review of Neurobiology","Psychedelics in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:53:10Z","timestamp":1750287190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443343858"],"references-count":127,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.009","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}